Literature DB >> 16048914

Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.

Charles R Dean1, Shubha Narayan, Denis M Daigle, JoAnn L Dzink-Fox, Xiaoling Puyang, Kathryn R Bracken, Karl E Dean, Beat Weidmann, Zhengyu Yuan, Rakesh Jain, Neil S Ryder.   

Abstract

Haemophilus influenzae isolates vary widely in their susceptibilities to the peptide deformylase inhibitor LBM415 (MIC range, 0.06 to 32 microg/ml); however, on average, they are less susceptible than gram-positive organisms, such as Staphylococcus aureus and Streptococcus pneumoniae. Insertional inactivation of the H. influenzae acrB or tolC gene in strain NB65044 (Rd strain KW20) increased susceptibility to LBM415, confirming a role for the AcrAB-TolC pump in determining resistance. Consistent with this, sequencing of a PCR fragment generated with primers flanking the acrRA region from an LBM415-hypersusceptible H. influenzae clinical isolate revealed a genetic deletion of acrA. Inactivation of acrB or tolC in several clinical isolates with atypically reduced susceptibility to LBM415 (MIC of 16 microg/ml or greater) significantly increased susceptibility, confirming that the pump is also a determinant of decreased susceptibility in these clinical isolates. Examination of acrR, encoding the putative repressor of pump gene expression, from several of these strains revealed mutations introducing frameshifts, stop codons, and amino acid changes relative to the published sequence, suggesting that loss of pump repression leads to decreased susceptibility. Supporting this, NB65044 acrR mutants selected by exposure to LBM415 at 8 microg/ml had susceptibilities to LBM415 and other pump substrates comparable to the least sensitive clinical isolates and showed increased expression of pump genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048914      PMCID: PMC1196275          DOI: 10.1128/AAC.49.8.3129-3135.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 2.  Transformation of Haemophilus influenzae.

Authors:  Grant Poje; Rosemary J Redfield
Journal:  Methods Mol Med       Date:  2003

3.  Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump.

Authors:  Edward W Yu; Gerry McDermott; Helen I Zgurskaya; Hiroshi Nikaido; Daniel E Koshland
Journal:  Science       Date:  2003-05-09       Impact factor: 47.728

4.  A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae.

Authors:  Brian J Akerley; Eric J Rubin; Veronica L Novick; Kensey Amaya; Nicholas Judson; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

5.  Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors:  Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops.

Authors:  Christopher A Elkins; Hiroshi Nikaido
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

7.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.

Authors:  R Dagan; C E Johnson; S McLinn; N Abughali; J Feris; E Leibovitz; D J Burch; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

8.  In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.

Authors:  R Wise; J M Andrews; J Ashby
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

9.  Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.

Authors:  Mihaela Peric; Bülent Bozdogan; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

10.  Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Authors:  Charles R Dean; Melissa A Visalli; Steven J Projan; Phaik-Eng Sum; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

View more
  16 in total

1.  Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.

Authors:  Charles R Dean; Shubha Narayan; Joel Richards; Denis M Daigle; Stacy Esterow; Jennifer A Leeds; Heather Kamp; Xiaoling Puyang; Brigitte Wiedmann; Dieter Mueller; Hans Voshol; Jan van Oostrum; Daniel Wall; James Koehn; Joann Dzink-Fox; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 2.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  XCC2366, A Gene Encoding A Putative TetR Family Transcriptional Regulator, is Required for Acriflavin Resistance and Virulence of Xanthomonas campestris pv. campestris.

Authors:  Chao-Tsai Liao; Hsueh-Hsia Lo; Weng-Ting Peng; Wan-Ling Song; Shin-Chiao Du; Yi-Min Hsiao
Journal:  Curr Microbiol       Date:  2017-08-18       Impact factor: 2.188

6.  Peptide deformylase inhibitors as potent antimycobacterial agents.

Authors:  Jeanette W P Teo; Pamela Thayalan; David Beer; Amelia S L Yap; Mahesh Nanjundappa; Xinyi Ngew; Jeyaraj Duraiswamy; Sarah Liung; Veronique Dartois; Mark Schreiber; Samiul Hasan; Michael Cynamon; Neil S Ryder; Xia Yang; Beat Weidmann; Kathryn Bracken; Thomas Dick; Kakoli Mukherjee
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

7.  Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.

Authors:  Ruth E Caughlan; Shubha Sriram; Denis M Daigle; Angela L Woods; Jennifer Buco; Ron L Peterson; Joann Dzink-Fox; Susan Walker; Charles R Dean
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

8.  First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.

Authors:  Marina Cerquetti; Maria Giufrè; Rita Cardines; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

9.  Inhibition of chlamydial infection in the genital tract of female mice by topical application of a peptide deformylase inhibitor.

Authors:  Amit Balakrishnan; Lingling Wang; Xiaojin Li; Pamela Ohman-Strickland; Paul Malatesta; Huizhou Fan
Journal:  Microbiol Res       Date:  2007-10-23       Impact factor: 5.415

10.  New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors.

Authors:  Laurent Mamelli; Sylvain Petit; Jacqueline Chevalier; Carmela Giglione; Aurélie Lieutaud; Thierry Meinnel; Isabelle Artaud; Jean-Marie Pagès
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.